References for: sentence

Full identifier: http://www.w3.org/2000/01/rdf-schema#sentence

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In vitro dexamethasone inhibited tissue inflammation via macrophages MerTK function.
Eva Zegelaar
2021-07-25T21:48:07.976Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
The MerTK-dependent anti-inflammatory mechanisms of dexamethasone, and the homeostatic function of TAM pathways that maintain RA in remission advocate the therapeutic MerTK agonism to ameliorate the cytokine storm and pneumonitis of severe COVID-19.
Eva Zegelaar
2021-07-25T21:48:06.253Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Simulations suggest that linoleate and dexamethasone stabilize the locked spike conformation, thus reducing the opportunity for ACE2 interaction.
Eva Zegelaar
2021-07-25T21:48:04.785Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Simulations suggest that linoleate and dexamethasone stabilize the locked spike conformation, thus reducing the opportunity for ACE2 interaction.
Eva Zegelaar
2021-07-25T21:48:03.393Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
A regimen of hydroxychloroquine, azithromycin, and dexamethasone was initiated on admission in 3 severe cases of COVID-19 pneumonia in cruise ship employees who were admitted to the ICU and responded to supportive mechanical ventilation and pulmonary hygiene management.
Eva Zegelaar
2021-07-25T21:48:01.913Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients.
Eva Zegelaar
2021-07-25T21:48:00.422Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation.
Eva Zegelaar
2021-07-25T21:47:58.637Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity.
Eva Zegelaar
2021-07-25T21:47:56.729Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity.
Eva Zegelaar
2021-07-25T21:47:55.281Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity.
Eva Zegelaar
2021-07-25T21:47:53.804Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy.
Eva Zegelaar
2021-07-25T21:47:52.320Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Advances in standard of care, recent emergency use authorizations, and positive data with dexamethasone have likely contributed to an increasing proportion of patients who are surviving without the need for mechanical ventilation.
Eva Zegelaar
2021-07-25T21:47:50.799Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
When dexamethasone was added to cover the possibility of COVID-19 pneumonia, a 71-year-old woman with bilateral pneumonia who continued to deteriorate despite multiple courses of antibiotics rapidly improved.
Eva Zegelaar
2021-07-25T21:47:49.295Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction.
Eva Zegelaar
2021-07-25T21:47:47.785Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Use of non-steroidal anti-inflammatories, dexamethasone and prophylactic antibiotics were associated with smaller reductions in LOS.
Eva Zegelaar
2021-07-25T21:47:46.311Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Severe acute respiratory distress coronavirus 2 (SARS)-CoV-2) virus is responsible for the current pandemic - coronavirus disease 2019 (COVID)-19) plaguing the world Severe acute respiratory distress coronavirus 2 (SARS)-CoV-2) virus began spreading as early as January 2020 in the United States (US) and has recently become the leading cause of death amongst adults over 45 years of age Much of Severe acute respiratory distress coronavirus 2 (SARS)-CoV-2) virus's clinical presentation is already known, and there have been advances in Severe acute respiratory distress coronavirus 2 (SARS)-CoV-2) virus's successful treatment with a food and drug administration (FDA) approved antiviral medication called remdesivir, and other proven investigational methods with clinical benefits including dexamethasone and Severe acute respiratory distress coronavirus 2 (SARS)-CoV-2) virus antibody transfusion called convalescent plasma therapy However, the recommendations for other proven investigational methods with clinical benefits including dexamethasone and COVID-19 antibody transfusion called convalescent plasma therapy's use include COVID-19 confirmed patients requiring supplemental oxygen or other forms of respiratory support In this case report, we describe in detail a unique case of severe Severe acute respiratory distress coronavirus 2 (SARS)-CoV-2) virus infection that did not require any form of oxygen support hut was treated successfully with antiviral medications and steroids The purpose of this case report is to highlight in detail an unusual Severe acute respiratory distress coronavirus 2 (SARS)-CoV-2) virus presentation with rhabdomyolysis, myocarditis, and pancytopenia severe enough to require hospitalization and treatment with proven Severe acute respiratory distress coronavirus 2 (SARS)-CoV-2) virus therapy to achieve clinical resolution
Eva Zegelaar
2021-07-25T21:47:44.864Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Although the therapeutic potential of certain repurposed drugs has led to certain repurposed drugs's off-label use against COVID-19, such as anti-retroviral drugs (remdesivir, favipiravir, and lopinavir-ritonavir combination), biologics (tocilizumab), antibiotics (azithromycin), antiparasitics (chloroquine and hydroxychloroquine), and corticosteroids (dexamethasone), unfortunately, the associated clinical neuropsychiatric adverse events remains a critical issue.
Eva Zegelaar
2021-07-25T21:47:43.303Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management.
Eva Zegelaar
2021-07-25T21:47:41.859Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
A clinical interpretation of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) study was performed to provide a useful tool to understand whether, when, and to whom dexamethasone should be administered during hospitalization for COVID-19 A post hoc analysis of data published in the preliminary report of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) study was performed to calculate the person-based number needed to treat (NNT) and number needed to harm (NNH) of 6 mg dexamethasone once daily for up to 10 days vs usual care with respect to mortality At day 28, the NNT of dexamethasone vs usual care was 36 0 (95%CI 24 9–65 1, p <0 05) in all patients, 8 3 (95%CI 6 0–13 1, p <0 05) in patients receiving invasive mechanical ventilation, and 34 6 (95%CI 22 1–79 0, p <0 05) in patients receiving oxygen only (with or without noninvasive ventilation) dexamethasone increased mortality compared with usual care in patients not requiring oxygen supplementation, leading to a NNH value of 26 7 (95%CI 18 1–50 9, p <0 05) NNT of dexamethasone vs usual care was 17 3 (95%CI 14 9–20 6) in subjects <70 years, 27 0 (95%CI 18 5–49 8) in men, and 16 2 (95%CI 13 2–20 8) in patients in which the onset of symptoms was >7 days dexamethasone is effective in male subjects <70 years that require invasive mechanical ventilation experiencing symptoms from >7 days and those patients receiving oxygen without invasive mechanical ventilation;it should be avoided in patients not requiring respiratory support
Eva Zegelaar
2021-07-25T21:47:40.361Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
A clinical interpretation of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) study was performed to provide a useful tool to understand whether, when, and to whom dexamethasone should be administered during hospitalization for COVID-19 A post hoc analysis of data published in the preliminary report of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) study was performed to calculate the person-based number needed to treat (NNT) and number needed to harm (NNH) of 6 mg dexamethasone once daily for up to 10 days vs usual care with respect to mortality At day 28, the NNT of dexamethasone vs usual care was 36 0 (95%CI 24 9–65 1, p <0 05) in all patients, 8 3 (95%CI 6 0–13 1, p <0 05) in patients receiving invasive mechanical ventilation, and 34 6 (95%CI 22 1–79 0, p <0 05) in patients receiving oxygen only (with or without noninvasive ventilation) dexamethasone increased mortality compared with usual care in patients not requiring oxygen supplementation, leading to a NNH value of 26 7 (95%CI 18 1–50 9, p <0 05) NNT of dexamethasone vs usual care was 17 3 (95%CI 14 9–20 6) in subjects <70 years, 27 0 (95%CI 18 5–49 8) in men, and 16 2 (95%CI 13 2–20 8) in patients in which the onset of symptoms was >7 days dexamethasone is effective in male subjects <70 years that require invasive mechanical ventilation experiencing symptoms from >7 days and those patients receiving oxygen without invasive mechanical ventilation;it should be avoided in patients not requiring respiratory support
Eva Zegelaar
2021-07-25T21:47:37.973Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers.
Eva Zegelaar
2021-07-25T21:47:35.599Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers.
Eva Zegelaar
2021-07-25T21:47:33.915Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In conclusion, dexamethasone treatment (2.5 mg.kg(-1)) from days 3-14 post inoculation has no beneficial effect on acute respiratory distress syndrome (ARDS) induced by the H5N1 viral infection in mice.
Eva Zegelaar
2021-07-25T21:47:32.424Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In the H5N1 viral infection in mice mice, dexamethasone (DEX) treatment did not improve the mortality (17 out of 20 versus 16 out of 20 deaths in the DEX-treated infected group DEX-treated versus The infected group), and did not alleviate clinical signs, including weight loss, decreased food intake and inactivity.
Eva Zegelaar
2021-07-25T21:47:30.965Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In the H5N1 viral infection in mice mice, dexamethasone (DEX) treatment did not improve the mortality (17 out of 20 versus 16 out of 20 deaths in the DEX-treated infected group DEX-treated versus The infected group), and did not alleviate clinical signs, including weight loss, decreased food intake and inactivity.
Eva Zegelaar
2021-07-25T21:47:29.453Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo.
Eva Zegelaar
2021-07-25T21:47:27.954Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
LESSONS This case report illustrates early use of INTERVENTION Use of intravenous remdesivir and dexamethasone might be beneficial in refractory Myasthenia gravis (MG) cases even with chronic immunosuppression and severe COVID-19 infection.
Eva Zegelaar
2021-07-25T21:47:26.443Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients.
Eva Zegelaar
2021-07-25T21:47:25.030Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In addition to many drugs being evaluated in clinical trials, the dexamethasone was top-ranked in the prediction, which was the first reported drug to be able to significantly reduce the death rate of COVID-19 patients receiving respiratory support.
Eva Zegelaar
2021-07-25T21:47:23.553Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In addition to many drugs being evaluated in clinical trials, the dexamethasone was top-ranked in the prediction, which was the first reported drug to be able to significantly reduce the death rate of COVID-19 patients receiving respiratory support.
Eva Zegelaar
2021-07-25T21:47:22.100Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Patients in the intervention group will receive dexamethasone 20 mg intravenously once daily on day 1-5, followed by dexamethasone 10 mg intravenously once daily on day 6-10.
Eva Zegelaar
2021-07-25T21:47:20.598Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
The primary objective of this study is to test the hypothesis that administration of dexamethasone 20 mg is superior to a 6 mg dose in adult patients with moderate or severe ARDS due to confirmed COVID-19.
Eva Zegelaar
2021-07-25T21:47:19.105Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
dexamethasone failed to demonstrate any protective advantage in terms of mitigating short-term PMCs or infectious complications, or to confer any long-term survival benefit.
Eva Zegelaar
2021-07-25T21:47:17.645Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
dexamethasone failed to demonstrate any protective advantage in terms of mitigating short-term PMCs or infectious complications, or to confer any long-term survival benefit.
Eva Zegelaar
2021-07-25T21:47:16.200Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
dexamethasone failed to demonstrate any protective advantage in terms of mitigating short-term PMCs or infectious complications, or to confer any long-term survival benefit.
Eva Zegelaar
2021-07-25T21:47:14.721Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90).
Eva Zegelaar
2021-07-25T21:47:13.306Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39).
Eva Zegelaar
2021-07-25T21:47:11.776Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection.
Eva Zegelaar
2021-07-25T21:47:10.357Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection.
Eva Zegelaar
2021-07-25T21:47:08.856Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
With suprachoroidal delivery, dexamethasone levels were detectable in choroid-retina unit (12.04 ± 20.85 ng/g) and sclera (25.46 ± 44.09 ng/g) up to week 24.
Eva Zegelaar
2021-07-25T21:47:07.442Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
OBJECTIVES The questions remained if mortality benefits with dexamethasone seen in patients with coronavirus disease 2019 (COVID)-19) also extend to other systemic corticosteroids such as methylprednisolone.
Eva Zegelaar
2021-07-25T21:47:05.979Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis.
Eva Zegelaar
2021-07-25T21:47:04.334Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In the preoperative submucosal corticosteroid injection group (n = 16), 8 mg/2 ml dexamethasone 21-phosphate was administered near operated sites.
Eva Zegelaar
2021-07-25T21:47:02.852Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In addition, randomized trials have demonstrated that dexamethasone improves outcomes in patients on mechanical ventilators or on oxygen.
Eva Zegelaar
2021-07-25T21:47:01.445Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
During the COVD-19 pandemic, some pediatric patients in many countries around the world experienced a syndrome resembling a severe Kawasaki disease (KD), often accompanied by shock Due to the incomplete signs of a severe Kawasaki disease (KD) in the era before the COVD-19 pandemic, in many publications from European countries and the United States, this condition was called «multisystem inflammatory syndrome in children – MIS-C» or «hyperinflammatory shock» or «Kawasaki-like syndrome» this condition is characterized by refractory fever, frequent gastrointestinal symptoms, heart damage (including coronary dilation in some patients, and acute left ventricular failure in the majority), increased ESR and CRP levels, neutrophilia, extremely high troponin levels, increased ferritin, AST, ALT, lactate dehydrogenase, creatine phosphate kinase, interleukin-6 and interleukin-10, coagulopathy with an increase in D-dimer and fibrinogen, thrombocytopenia, sometimes procalcitonin increase The manifestations of a cytokine storm may meet the criteria for secondary hemophagocytic syndrome The mechanism of myocardial damage remains unclear Treatment with high-dose intravenous immunoglobulin is effective, and in the presence of signs of hemophagocytic syndrome, dexamethasone or methylprednisolone Further research is needed to understand the pathogenesis, resemblance and differences of this syndrome with a severe Kawasaki disease (KD), understanding of heart injuiry and early recognition for the need of urgent care
Eva Zegelaar
2021-07-25T21:46:59.912Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
During the COVD-19 pandemic, some pediatric patients in many countries around the world experienced a syndrome resembling a severe Kawasaki disease (KD), often accompanied by shock Due to the incomplete signs of a severe Kawasaki disease (KD) in the era before the COVD-19 pandemic, in many publications from European countries and the United States, this condition was called «multisystem inflammatory syndrome in children – MIS-C» or «hyperinflammatory shock» or «Kawasaki-like syndrome» this condition is characterized by refractory fever, frequent gastrointestinal symptoms, heart damage (including coronary dilation in some patients, and acute left ventricular failure in the majority), increased ESR and CRP levels, neutrophilia, extremely high troponin levels, increased ferritin, AST, ALT, lactate dehydrogenase, creatine phosphate kinase, interleukin-6 and interleukin-10, coagulopathy with an increase in D-dimer and fibrinogen, thrombocytopenia, sometimes procalcitonin increase The manifestations of a cytokine storm may meet the criteria for secondary hemophagocytic syndrome The mechanism of myocardial damage remains unclear Treatment with high-dose intravenous immunoglobulin is effective, and in the presence of signs of hemophagocytic syndrome, dexamethasone or methylprednisolone Further research is needed to understand the pathogenesis, resemblance and differences of this syndrome with a severe Kawasaki disease (KD), understanding of heart injuiry and early recognition for the need of urgent care
Eva Zegelaar
2021-07-25T21:46:58.429Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
The aim of the study was to test the hypothesis that pre-emptive scalp infiltration with a steroid (dexamethasone) plus a local anesthetic (ropivacaine) could achieve superior postoperative analgesic effects to a local anesthetic (ropivacaine) alone in adult patients undergoing a craniotomy.
Eva Zegelaar
2021-07-25T21:46:56.935Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Recently, local infiltration of analgesia (LIA) has been widely performed clinically as a promising analgesic method that could avoid the side effects of analgesics but only has a short pain-free duration; researchers have clarified that the addition of dexamethasone to local infiltration of analgesia (LIA) could provide significant analgesic effects and significantly prolong the duration of analgesic effects without obvious complications for various types of surgeries.
Eva Zegelaar
2021-07-25T21:46:55.489Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Recently, local infiltration of analgesia (LIA) has been widely performed clinically as a promising analgesic method that could avoid the side effects of analgesics but only has a short pain-free duration; researchers have clarified that the addition of dexamethasone to local infiltration of analgesia (LIA) could provide significant analgesic effects and significantly prolong the duration of analgesic effects without obvious complications for various types of surgeries.
Eva Zegelaar
2021-07-25T21:46:53.990Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
CONCLUSION Clear evidence of a beneficial or negative effect of dexamethasone is still lacking.
Eva Zegelaar
2021-07-25T21:46:52.565Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Modern RCTs or observational studies with propensity design are necessary to evaluate the efficacy and safety of treatment with dexamethasone in patients with BACKGROUND Spontaneous intracerebral hemorrhage (ICH).
Eva Zegelaar
2021-07-25T21:46:51.057Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation.
Eva Zegelaar
2021-07-25T21:46:49.621Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality.
Eva Zegelaar
2021-07-25T21:46:48.148Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality.
Eva Zegelaar
2021-07-25T21:46:45.913Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
A 78-year-old man fell from a ladder and suffered a right distal tibial fracture On the seventh day after injury, A 78-year-old man developed a low-grade fever and was isolated in a private room Polymerase chain reaction for COVID-19 was positive (day 4 from the day of saliva sampling) On day 5, A 78-year-old man required 1 liter per minute of oxygen and dexamethasone therapy was initiated On day 6, A 78-year-old man's D-dimer level was 25 0 mu g/mL, and continuous infusion of heparin was initiated From day 7, A 78-year-old man was administered remdesivir On day 9, A 78-year-old man's oxygenation suddenly showed a remarkable deterioration A 78-year-old man received a tentative diagnosis of COVID-19-induced pneumonia accompanied by severe acute respiratory distress syndrome (ARDS) and underwent urgent tracheal intubation and mechanical ventilation A 78-year-old man also received intravenous immunoglobulin (IVIG) and was also administered glycyrrhizin his oxygenation gradually improved and extubation was performed on day 15 Following rehabilitation, A 78-year-old man did not require oxygen on day 19 On day 20, A 78-year-old man's D-dimer level was found to be increased and enhanced computed tomography revealed pulmonary embolism A 78-year-old man was prescribed a direct oral anticoagulant On day 28 A 78-year-old man was transferred to a general ward for rehabilitation These unspecific antiviral therapies and immune modulation therapy may be useful treatments for the main cause of severe acute respiratory distress syndrome (ARDS), which may explain the favorable outcome that was obtained in the present case
Eva Zegelaar
2021-07-25T21:46:44.411Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
dexamethasone failed to demonstrate any protective advantage in terms of mitigating short-term PMCs or infectious complications, or to confer any long-term survival benefit.
Eva Zegelaar
2021-07-25T21:46:42.965Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
we's studies demonstrated that LABAs and dexamethasone exert synergistic effects that will augment both anti-inflammatory and fibronectin-mediated anticoagulant effects.
Eva Zegelaar
2021-07-25T21:46:41.041Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
we's results indicated that combining dexamethasone with fast long-acting beta-2 adrenergic agonists (LABAs), such as formoterol and salmeterol, can ease respiratory symptoms hastily, until dexamethasone's anti-inflammatory and immunosuppressant effects kick in.
Eva Zegelaar
2021-07-25T21:46:38.448Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
When appropriate, administration of adjunctive dexamethasone with the antibiotics often lessens neurologic sequelae in survivors, which may include aphasia, ataxia, paresis, hearing loss, and cognitive impairment.
Eva Zegelaar
2021-07-25T21:46:36.961Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Our purpose was to minimize dexamethasone exposure during antiemetic prophylaxis for systemic therapy for solid tumors during the COVID-19 pandemic, while maintaining control of nausea and emesis.
Eva Zegelaar
2021-07-25T21:46:35.465Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Single-day dexamethasone dosing is recommended over multi-day dosing for regimens with high emetogenic risk excluding high-dose cisplatin, preferably in combination with palonosetron, netupitant, and olanzapine.
Eva Zegelaar
2021-07-25T21:46:33.903Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In Intervention Group 2, the administration of dexamethasone will be started within the first 24 hours' time of admission and will be continued for 48-72 hours and then the level of SpO2 will be checked.
Eva Zegelaar
2021-07-25T21:46:32.502Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In Intervention Group 2, the administration of dexamethasone will be started within the first 24 hours' time of admission and will be continued for 48-72 hours and then the level of SpO2 will be checked.
Eva Zegelaar
2021-07-25T21:46:31.030Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19.
Eva Zegelaar
2021-07-25T21:46:29.565Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In order to increase the therapeutic efficacy of dexamethasone in COVID-19 patients, while minimizing dexamethasone-related complications that could result from using higher doses of dexamethasone, we applied a chemocentric informatics approach to identify combination therapies.
Eva Zegelaar
2021-07-25T21:46:28.097Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation.
Eva Zegelaar
2021-07-25T21:46:26.691Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Favipiravir, ciclesonide, dexamethasone, and heparin were administered in 106, 168, 65, and 38 patients, respectively, but not remdesivir.
Eva Zegelaar
2021-07-25T21:46:25.209Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
We recommend that inpatients who require supplemental oxygen but are not mechanically ventilated receive The antiviral agent, remdesivir, and the immunomodulator, dexamethasone, and inpatients who require mechanical ventilation receive the immunomodulator, dexamethasone monotherapy.
Eva Zegelaar
2021-07-25T21:46:23.789Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
To target the inflammatory cascade, low-dose dexamethasone appears to be helpful in moderate to severe cases and trials with anti-interleukin agents (e.g., tocilizumab, anakinra, siltuximab) and non-steroidal anti-inflammatory drugs are showing early promising results.
Eva Zegelaar
2021-07-25T21:46:22.302Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
To target the inflammatory cascade, low-dose dexamethasone appears to be helpful in moderate to severe cases and trials with anti-interleukin agents (e.g., tocilizumab, anakinra, siltuximab) and non-steroidal anti-inflammatory drugs are showing early promising results.
Eva Zegelaar
2021-07-25T21:46:20.879Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
SESSION Medical Student/Resident Lung Cancer Posters SESSION Med Student/Res Case Rep Postr PRESENTED October 18-21, 2020 The COVID-19 pandemic has set a precedent for medicine, especially vulnerable immunocompromised patients Cancer patients are facing a dilemma, uncertain of especially vulnerable immunocompromised patients Cancer patients's treatment course, and the serious risk of contracting the viral illness, all while there is no current research showing mortality rates in especially vulnerable immunocompromised patients Cancer patients Postr present a rapidly evolving undiagnosed COVID-19 patient after chemotherapy initiation for a recent lung cancer diagnosis CASE A 64-year-old Caucasian male with a history of COPD, tobacco use and a recent diagnosis of lung cancer presented to the emergency department after experiencing palpitations and 10 days of malaise and dyspnea on exertion Prior to presented, a rapidly evolving undiagnosed COVID-19 patient after chemotherapy initiation for a recent lung cancer diagnosis underwent lung cancer screening with a CT chest scan on April 19, 2020 (baseline CT chest, Figure 1) The results showed a left lower lobe mass without infiltrates, subsequently biopsied and confirmed small cell lung carcinoma Upon presentation to Postr's hospital on May 1, 2020, a rapidly evolving undiagnosed COVID-19 patient after chemotherapy initiation for a recent lung cancer diagnosis's labs were significant for – absolute lymphocyte count (745), D-dimer (4 33), NT-proBNP (2149), troponin (0 05), ALT (97), AST (87), creatinine (1 39) There was no evidence of an elevated total WBC, abnormal thyroid studies or any labs suggestive of paraneoplastic syndrome a rapidly evolving undiagnosed COVID-19 patient after chemotherapy initiation for a recent lung cancer diagnosis's initial ECG showed atrial flutter with a rapid ventricular rate CT chest showed honeycombing lesions in the central right lobe and around the left lobe near the lung mass (Figure 2) Given a rapidly evolving undiagnosed COVID-19 patient after chemotherapy initiation for a recent lung cancer diagnosis's hemodynamic instability, a rapidly evolving undiagnosed COVID-19 patient after chemotherapy initiation for a recent lung cancer diagnosis was admitted to the ICU and successfully cardioverted following a negative TEE A respiratory PCR panel returned negative on May 4 (did not include COVID-19) Chemotherapy was initiated with carboplatin, etoposide and dexamethasone A follow-up CT chest revealed evolution of the honeycombing lesions, now spread diffusely, raising concern for COVID-19 (Figure 3) A COVID-19 NAAT returned positive on May 6 This case illustrates the increased susceptibility of cancer patients to COVID-19 Given this, Postr recommend pre-emptive COVID-19 testing for all patients prior to starting any chemotherapy Secondly, This case serves as an example of the rapid evolution of COVID-19, and the benefits of repeated imaging Prior reports from Chinese patients showed bilateral infiltrates upon admission 79% of the time and median 5 days of symptom onset to admission (Zhao1) CT chest scans typically showed ground glass opacities and bilateral patchy shadowing (Guan2, Shi3) If testing is not readily available or turn-around time is prolonged, repeat CT chest scans can help guide treatment Having a baseline CT chest helped initiate testing for COVID-19 after Guan2's symptoms worsened once Guan2 received chemotherapy The evolution is rapid, requiring a high index of suspicion for diagnosis and extensive testing to monitor the course in these patients This case hopes to set a standard for similar patients Reference #1: Zhao1, Yao F, Wang L, et al A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias Clinical Infectious Diseases, ciaa247, March 12, 2020 https://academic oup com/cid/advance-article/doi/10 1093/cid/ciaa247/5803302external icon Reference #2: Guan2, Ni ZY, Hu Y, et al Clinical Characteristics of Coronavirus Disease 2019 in Chinaexternal icon N Engl J Med February 28, 2020 10 1056/NEJMoa2002032 Reference #3: Shi H, Han X, Jiang N, et al Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study The Lancet Published online February 24, 2020 https://www sciencedirect com/science/article/pii/S1473309920300864 10 1016/S1473-3099(20)30086-4 No relevant relationships by Ralph Apolinario, source=Web Response No relevant relationships by Oziel Garza de la Garza, source=Web Response No relevant relationships by James Hanley, source=Web Response No relevant relationshi s by Luyang Jin, source=Web Response No relevant relationships by Ayman Khaddam, source=Web Response No relevant relationships by Henderson Lopez, source=Web Response No relevant relationships by Jeann Maldonado Cintron, source=Web Response No relevant relationships by Earl Mejia, source=Web Response No relevant relationships by Alberto Montalvo, source=Web Response No relevant relationships by Rafael Otero, source=Web Response No relevant relationships by Nayeli Zarate, source=Web Response
Eva Zegelaar
2021-07-25T21:46:19.355Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone can be an effective intervention to increase COVID-19 survival rates in patients at risk of developing a COVID-19 hyper-inflammatory response, laboratory marker tests can be used to stratify these patients.
Eva Zegelaar
2021-07-25T21:46:17.902Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Test whether high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone is associated with increased survival in COVID-19 patients at risk of hyper-inflammatory response.
Eva Zegelaar
2021-07-25T21:46:16.383Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Remdesivir, dexamethasone, azithromycin, favipiravir, lopinavir/ritonavir, atazanavir, hydroxychloroquine, interferon beta, ribavirin, tocilizumab, anakinra and sarilumab were identified as experimental drugs being used in the associated coronavirus disease 2019 (COVID)-19) trials as of November 2020.
Eva Zegelaar
2021-07-25T21:46:13.433Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Low-dose dexamethasone therapy currently is the best therapeutic approach.
Eva Zegelaar
2021-07-25T21:46:12.011Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Purpose: To determine the preference of patients undergoing bilateral LASIK for either the dexamethasone intracanalicular insert or topical prednisolone acetate for control of postoperative symptoms and ocular surface signs Methods: In this randomized clinical trial, one eye was randomized to receive the dexamethasone intracanalicular insert or topical prednisolone acetate topical prednisolone acetate 1% four times daily for one week and 2 times daily for a second week;the fellow eye received the alternate therapy One month postoperatively, patient preference for the dexamethasone intracanalicular insert or topical prednisolone acetate was assessed using an adapted COMTOL questionnaire Ocular comfort was assessed using the SPEED questionnaire Corneal staining and uncorrected distance visual acuity (UDVA) were also assessed Results: Twenty patients participated At Month 1, 80% of patients preferred the dexamethasone intracanalicular insert, 10% preferred topical prednisolone acetate, and 10% expressed no preference (p 0 001) SPEED scores measuring ocular comfort/discomfort related to dry eye symptoms were similar between groups (p=0 72), and both the incidence of patient-reported ocular dryness and the corneal staining scores were similar between groups Both groups attained the same final uncorrected distance visual acuity (UDVA) Conclusion: Patients undergoing elective bilateral femtosecond LASIK surgery overwhelmingly (by an 8-to-1 margin) preferred the dexamethasone intracanalicular insert to topical prednisolone acetate for postoperative treatment the dexamethasone intracanalicular insert produced comparable ocular comfort, corneal staining, and visual acuity outcomes to topical prednisolone acetate the dexamethasone intracanalicular insert is an appropriate means of postoperative symptom control in this quality of life-conscious population
Eva Zegelaar
2021-07-25T21:46:10.495Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Purpose: To determine the preference of patients undergoing bilateral LASIK for either the dexamethasone intracanalicular insert or topical prednisolone acetate for control of postoperative symptoms and ocular surface signs Methods: In this randomized clinical trial, one eye was randomized to receive the dexamethasone intracanalicular insert or topical prednisolone acetate topical prednisolone acetate 1% four times daily for one week and 2 times daily for a second week;the fellow eye received the alternate therapy One month postoperatively, patient preference for the dexamethasone intracanalicular insert or topical prednisolone acetate was assessed using an adapted COMTOL questionnaire Ocular comfort was assessed using the SPEED questionnaire Corneal staining and uncorrected distance visual acuity (UDVA) were also assessed Results: Twenty patients participated At Month 1, 80% of patients preferred the dexamethasone intracanalicular insert, 10% preferred topical prednisolone acetate, and 10% expressed no preference (p 0 001) SPEED scores measuring ocular comfort/discomfort related to dry eye symptoms were similar between groups (p=0 72), and both the incidence of patient-reported ocular dryness and the corneal staining scores were similar between groups Both groups attained the same final uncorrected distance visual acuity (UDVA) Conclusion: Patients undergoing elective bilateral femtosecond LASIK surgery overwhelmingly (by an 8-to-1 margin) preferred the dexamethasone intracanalicular insert to topical prednisolone acetate for postoperative treatment the dexamethasone intracanalicular insert produced comparable ocular comfort, corneal staining, and visual acuity outcomes to topical prednisolone acetate the dexamethasone intracanalicular insert is an appropriate means of postoperative symptom control in this quality of life-conscious population
Eva Zegelaar
2021-07-25T21:46:09.024Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Likewise, dexamethasone has been recently claimed to be effective in patients in need of respiratory assistance.
Eva Zegelaar
2021-07-25T21:46:07.548Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Therefore, while the anticoagulant heparin's multitarget capacity shows to be strongly beneficial for severe COVID-19 patients, the anti-inflammatory corticosteroid dexamethasone should be carefully administered taking into consideration underlying medical conditions and COVID-19 disease severity.
Eva Zegelaar
2021-07-25T21:46:06.144Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Importantly, the anti-inflammatory corticosteroid dexamethasone may be detrimental by impairing viral clearance and inducing hyperglycemia and sodium retention, hence possibly being deleterious for diabetics and hypertensive patients, two major COVID-19 risk groups.
Eva Zegelaar
2021-07-25T21:46:04.643Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Importantly, the anti-inflammatory corticosteroid dexamethasone may be detrimental by impairing viral clearance and inducing hyperglycemia and sodium retention, hence possibly being deleterious for diabetics and hypertensive patients, two major COVID-19 risk groups.
Eva Zegelaar
2021-07-25T21:46:03.230Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Importantly, the anti-inflammatory corticosteroid dexamethasone may be detrimental by impairing viral clearance and inducing hyperglycemia and sodium retention, hence possibly being deleterious for diabetics and hypertensive patients, two major COVID-19 risk groups.
Eva Zegelaar
2021-07-25T21:46:01.720Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Although the anti-inflammatory corticosteroid dexamethasone's administration for viral infection managing is controversial, there is increasing evidence demonstrating that the anti-inflammatory corticosteroid dexamethasone treatment is capable of drastically diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome (ARDS) that required invasive mechanical ventilation.
Eva Zegelaar
2021-07-25T21:46:00.259Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Although the anti-inflammatory corticosteroid dexamethasone's administration for viral infection managing is controversial, there is increasing evidence demonstrating that the anti-inflammatory corticosteroid dexamethasone treatment is capable of drastically diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome (ARDS) that required invasive mechanical ventilation.
Eva Zegelaar
2021-07-25T21:45:58.684Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Although the anti-inflammatory corticosteroid dexamethasone's administration for viral infection managing is controversial, there is increasing evidence demonstrating that the anti-inflammatory corticosteroid dexamethasone treatment is capable of drastically diminishing the death rate of patients presenting with Acute Respiratory Distress Syndrome (ARDS) that required invasive mechanical ventilation.
Eva Zegelaar
2021-07-25T21:45:57.215Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
A regimen of hydroxychloroquine, azithromycin, and dexamethasone was initiated on admission in 3 severe cases of COVID-19 pneumonia in cruise ship employees who were admitted to the ICU and responded to supportive mechanical ventilation and pulmonary hygiene management.
Eva Zegelaar
2021-07-25T21:45:55.668Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
Eva Zegelaar
2021-07-25T21:45:54.242Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Conclusions and Relevance Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over the first 28 days.
Eva Zegelaar
2021-07-25T21:45:52.714Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Objective To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19-associated ARDS.
Eva Zegelaar
2021-07-25T21:45:51.262Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
Thirty-three patients (21.9%) in the dexamethasone group vs 43 (29.1%) in the standard care group experienced secondary infections, 47 (31.1%) vs 42 (28.3%) needed insulin for glucose control, and 5 (3.3%) vs 9 (6.1%) experienced other serious adverse events.
Eva Zegelaar
2021-07-25T21:45:49.773Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
At present, several existing licensed drugs such as chloroquine, hydroxychloroquine, methylprednisolone, dexamethasone, and remdesivir have been used because of several existing licensed drugs such as chloroquine, hydroxychloroquine, methylprednisolone, dexamethasone, and remdesivir's potential efficacy in inhibiting COVID-19.
Eva Zegelaar
2021-07-25T21:45:48.290Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
The study demonstrates that dexamethasone (Dex) could bind to both the viral and host receptors as a potential drug candidate for COVID-19.
Eva Zegelaar
2021-07-25T21:45:46.794Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
The study demonstrates that dexamethasone (Dex) could bind to both the viral and host receptors as a potential drug candidate for COVID-19.
Eva Zegelaar
2021-07-25T21:45:45.370Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
We can conclude that dexamethasone would have a better result in hospitalized patients, especially in low-resources settings.
Eva Zegelaar
2021-07-25T21:45:43.881Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
The examples of results from trials studying dexamethasone and hydroxychloroquine for treatment of COVID-19 have had contrasting outcomes, including the potential for significant numbers of lives saved with the early release of results from the RECOVERY trial studying dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine.
Eva Zegelaar
2021-07-25T21:45:42.454Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
The examples of results from trials studying dexamethasone and hydroxychloroquine for treatment of COVID-19 have had contrasting outcomes, including the potential for significant numbers of lives saved with the early release of results from the RECOVERY trial studying dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine.
Eva Zegelaar
2021-07-25T21:45:40.898Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
In conclusion, this multicenter, open-label and phase IIa study demonstrated that multiple alternate dosing of NEPA (netupitant/palonosetron) without the addition of dexamethasone is highly effective for preventing nausea and vomiting in this difficult setting, with a good tolerability profile.
Eva Zegelaar
2021-07-25T21:45:39.442Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
To date, only dexamethasone and remdesivir have been shown to be effective, but several other promising candidates are in trials.
Eva Zegelaar
2021-07-25T21:45:37.960Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
To date, only dexamethasone and remdesivir have been shown to be effective, but several other promising candidates are in trials.
Eva Zegelaar
2021-07-25T21:45:36.473Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
sentence
dexamethasone increased mortality compared with usual care in patients not requiring oxygen supplementation, leading to a NNH value of 26.7 (95%CI 18.1–50.9, p < 0.05).
Eva Zegelaar
2021-07-21T12:01:30.231Z